Aflac Inc Price Target Revised by Morgan Stanley

Investing.com– Morgan Stanley (NYSE:MS) has reduced its price target for Aflac Inc (NYSE:AFL) due to weaker-than-expected margin guidance revealed during the company’s analyst briefing.

The brokerage cut the price target to $107 from $110 but maintained an "Equal-weight" rating for Aflac.

Reasons for Revision

The changes arise from Aflac's new guidance regarding its Japan and U.S. operations, detailing lower margin expectations. According to Morgan Stanley analysts, this adjustment is a result of strategic emphasis on long-term growth.

• Japan Operations: Margin decline relates to attracting younger customers, reinvestments for growth, and a normalization of margins.
• U.S. Operations: Pressures come from higher benefit ratios and increasing expenses linked to growth initiatives.

Adjusted Earnings Projections

Consequently, Morgan Stanley revised its earnings projections, lowering estimates for Aflac’s earnings per share (EPS) by 4% to 7% from 2025 to 2027.

Investment Thesis Uncertainty

While the new guidance reinforces Aflac’s growth-focused strategy, it introduces uncertainty, particularly for investors prioritizing near-term margin stability, as noted in the research report.

Despite these concerns, Morgan Stanley kept its "Equal-weight" rating, highlighting favorable long-term prospects. Aflac’s leadership aims to leverage demographic trends like aging populations and rising healthcare costs to enhance growth in both Japan and U.S. markets.

The insurer seeks to utilize its competitive advantages, including strong brand recognition and robust distribution channels. Analysts recognize these strengths but caution that market appreciation of Aflac's long-term growth potential may take time.

Conclusion

While Aflac's stock may experience near-term challenges, the strategic shift towards sustainable growth presents a promising narrative, according to analysts.